Clobetasol propionate

ApprovedSmall molecule

Bayer

Clobetasol propionate is one of 245 small molecule programs targeting Oral Lichen Planus. It is currently in Approved.

Indications

Total Trials

Active Trials

244

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oral Lichen PlanusActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

CataractActive, not recruiting

DermatitisActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

PsoriasisActive, not recruiting

Atopic DermatitisActive, not recruiting

Alopecia AreataActive, not recruiting

GrowthActive, not recruiting

Oral Lichen PlanusPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

CataractPhase 3

Active, not recruiting

DermatitisApproved

Active, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

PsoriasisApproved

Active, not recruiting

Atopic DermatitisPhase 1

Active, not recruiting

Alopecia AreataApproved

Active, not recruiting

GrowthPhase 3

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Clobetasol propionate

Bayer

Approved

1 2

Rituxan

Roche

Preclinical

61 3

Orencia

Bristol-Myers Squibb

Preclinical

47 4

Cimzia

UCB

Preclinical

30 5

Arcoxia

Novartis

Preclinical

4 6

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 7

Ilaris

Novartis

Preclinical

3 8

Actos

Takeda

Preclinical

2 9

Celexa

AbbVie

Preclinical

1 10

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cataract3 trials

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)

Completed·SSalvat·Phase 3·NCT04249076·215 enrolled

Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population

Recruiting·SSalvat·Phase 3·NCT05724446·60 enrolled

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)

Completed·SSalvat·Phase 3·NCT04246801·250 enrolled

Oral Lichen Planus2 trials

Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus.

Active, not recruiting·MMalmö University·Phase 2/3·NCT04364555·90 enrolled

Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus

Unknown status·GGarlapati Komali·Phase 2·NCT03026478·30 enrolled

Psoriasis2 trials

BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test

Completed· Bayer logo

Bayer·Phase 1·NCT02940002·23 enrolled

Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis

Completed·GGalderma R&D·Phase 4·NCT00733954·250 enrolled

Vulvar Lichen Sclerosus1 trial

Vulvar Lichen Sclerosus: Comparison Between Clobetasol Propionate, Photodynamic Therapy and Low-Intensity Laser

Completed·DDaniela de Fátima Teixeira da Silva·N/A·NCT02416531·30 enrolled

Growth1 trial

Plasma Rich in Growth Factors (PRGF) for the Treatment of Lichen Sclerosus Atrophicus of the Vulva

Withdrawn·FFundación Eduardo Anitua·Phase 3·NCT05364515

8 more indications

Treatment1 trial

Intra-oral Treatment of OLP With Rivelin®-CLO Patches

Completed·DDermtreat·Phase 2·NCT03592342·140 enrolled

Metastatic Colorectal Cancer1 trial

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Completed·—·Phase 2·NCT02368886·123 enrolled

Tics1 trial

BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study

Terminated· Bayer logo

Bayer·Phase 1·NCT02936492·32 enrolled

Dermatitis1 trial

Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis

Completed· GSK logo

GSK·Phase 4·NCT00828464·30 enrolled

Rheumatoid Arthritis1 trial

Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients

Unknown status·—·Phase 3·NCT04649697·39 enrolled

Alopecia Areata1 trial

Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata

Completed·—·Phase 4·NCT03535233·40 enrolled

Skin1 trial

A Study Assessing GW870086's Potential to Cause Skin Thinning

Completed· GSK logo

GSK·Phase 1·NCT01381445·20 enrolled

Atopic Dermatitis1 trial

A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)

Completed· LEO Pharma logo

LEO Pharma·Phase 1·NCT02376049·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Clobetasol propionate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Clobetasol propionate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Clobetasol propionate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Bayer

Clobetasol propionate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cataract3 trials

Oral Lichen Planus2 trials

Psoriasis2 trials

Vulvar Lichen Sclerosus1 trial

Growth1 trial

Treatment1 trial

Metastatic Colorectal Cancer1 trial

Tics1 trial

Dermatitis1 trial

Rheumatoid Arthritis1 trial

Alopecia Areata1 trial

Skin1 trial

Atopic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News